{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T21:38:23.547387+00:00","company":{"ticker":"CPIX","cik":1087294,"company_name":"CUMBERLAND PHARMACEUTICALS INC"},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"2923a815c5d9df7160069f91e9201e7278ecf2df","cik":1087294,"ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"$0.13 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss for the first quarter of 2026 was approximately $3.3 million","period_text":"three months ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"$9.1 million"},"claim":"CUMBERLAND PHARMACEUTICALS INC reported three months ended March 31, 2026 results: revenue $9.1 million, net income net loss for the first quarter of 2026 was approximately $3.3 million, EPS $0.13 per share.","evidence_excerpt":"Pharmaceuticals Inc. (Nasdaq: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during the first quarter of 2026. Cumberland ended the quarter with $71.0 million in total assets, $49.7 million in liabilities and $21.6 million of shareholders’ equity. “We","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001087294-26-000046","anchor_url":"https://secwatch.observer/filing/0001087294-26-000046#claim-2923a815c5d9df7160069f91e9201e7278ecf2df","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000046/0001087294-26-000046-index.htm"},{"fact_type":"material_agreement","fact_key":"4ae37d7ca72657ef4362aec7c9559adb7810bc6c","cik":1087294,"ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2026-04-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Asset Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Apotex Inc.","effective_date":"2026-04-22","item_codes_triggered":["1.01"],"value_text":"$100,000,000"},"claim":"CUMBERLAND PHARMACEUTICALS INC entered into Asset Purchase Agreement with Apotex Inc. valued at $100,000,000 (effective 2026-04-22).","evidence_excerpt":"On April 22, 2026, Cumberland Pharmaceuticals Inc. (the “ Company ” or “ Cumberland ”) entered into a strategic transaction (the “ Transaction ”) to integrate its commercial products with the U.S. branded business of an affiliate of Apotex Inc., a corporation incorporated under the laws of the Province of Ontario (“ Apotex ”), in exchange for $100,000,000 payable at the closing of the Transaction.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-047335","anchor_url":"https://secwatch.observer/filing/0001104659-26-047335#claim-4ae37d7ca72657ef4362aec7c9559adb7810bc6c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1087294/000110465926047335/0001104659-26-047335-index.htm"},{"fact_type":"debt_financing","fact_key":"76670528715e18a6bdf408d7b612ab6005bf3a8f","cik":1087294,"ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2025-11-24T23:59:59+00:00","payload":{"counterparty":"Pinnacle Bank","effective_date":"2025-11-18","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"Benchmark Term SOFR plus 2.75%","item_codes_triggered":["2.03"],"maturity_text":"October 1, 2027","principal_text":"up to $15 million"},"claim":"CUMBERLAND PHARMACEUTICALS INC incurred revolving credit of up to $15 million with Pinnacle Bank at Benchmark Term SOFR plus 2.75% maturing October 1, 2027.","evidence_excerpt":"The Amendment provides for a principal available for borrowing of up to $15 million.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001087294-25-000023","anchor_url":"https://secwatch.observer/filing/0001087294-25-000023#claim-76670528715e18a6bdf408d7b612ab6005bf3a8f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1087294/000108729425000023/0001087294-25-000023-index.htm"},{"fact_type":"earnings_release","fact_key":"cbc72b255023dfbfc637ff61e5aa46804e644a03","cik":1087294,"ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three months ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$8.5 million"},"claim":"CUMBERLAND PHARMACEUTICALS INC reported the three months ended March 31, 2024 results: revenue $8.5 million.","evidence_excerpt":"Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders’ equity. “It","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-021185","anchor_url":"https://secwatch.observer/filing/0001628280-24-021185#claim-cbc72b255023dfbfc637ff61e5aa46804e644a03","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024021185/0001628280-24-021185-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f2fa7176030a62c45fe1311cc75c952e17984e82","cik":1087294,"ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-23","outcome":"passed","proposal_text":"Ratification of appointment of Carr, Riggs & Ingram, LLC as independent registered public accounting firm for year ending December 31, 2024","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"28,560","votes_against":"15,502","votes_for":"11,189,440","votes_withheld":null}]},"claim":"CUMBERLAND PHARMACEUTICALS INC shareholders approved Ratification of appointment of Carr, Riggs & Ingram, LLC as independent registered public accounting firm for year ending December 31, 2024 at the 2024-04-23 meeting.","evidence_excerpt":"Appointment of Carr, Riggs & Ingram LLC as our independent registered public accounting firm for the year ending December 31, 2024 11,189,440 15,502 — 28,560 99.9%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-019053","anchor_url":"https://secwatch.observer/filing/0001628280-24-019053#claim-f2fa7176030a62c45fe1311cc75c952e17984e82","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024019053/0001628280-24-019053-index.htm"},{"fact_type":"shareholder_vote","fact_key":"09c219b79e806686f3c8210de96fd4bd329eb13d","cik":1087294,"ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-04-29T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-23","outcome":"passed","proposal_text":"Election of two Class II Directors","proposal_type":"director_election","results":[{"broker_non_votes":null,"subject":"Martin S. Brown, Jr.","votes_abstain":null,"votes_against":null,"votes_for":"8,544,756","votes_withheld":"352,239"},{"broker_non_votes":null,"subject":"James R. Jones","votes_abstain":null,"votes_against":null,"votes_for":"8,411,468","votes_withheld":"485,527"}]},"claim":"CUMBERLAND PHARMACEUTICALS INC shareholders approved Election of two Class II Directors at the 2024-04-23 meeting.","evidence_excerpt":"For Against Withheld Abstentions % of Votes in Favor Martin S. Brown, Jr. 8,544,756 — 352,239 — 96.0% James R. Jones 8,411,468 — 485,527 — 94.5%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-24-019053","anchor_url":"https://secwatch.observer/filing/0001628280-24-019053#claim-09c219b79e806686f3c8210de96fd4bd329eb13d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024019053/0001628280-24-019053-index.htm"}]}